Doxorubicin prodrugs with reduced cytotoxicity suited for tumour-specific activation

Anti-Cancer Drug Design

Volumn 13, Issue 8, 1998, Pages 955-968

  Desbène, Stéphanie ^a   Van Dufat Trinh, Hanh ^a   Michel, Sylvie ^a   Koch, Michel ^a   Tillequin, François ^a   Fournier, Geneviève ^b   Farjaudon, Nicole ^c   Monneret, Claude ^c  

^a CNRS   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c INSTITUT CURIE   (France)

Author keywords

ADEPT; Anthracyclines; Doxorubicin; PMT; Prodrugs

Indexed keywords

BETA GLUCURONIDASE; DOXORUBICIN DERIVATIVE; PRODRUG;

ARTICLE; CARCINOMA CELL; DRUG CYTOTOXICITY; DRUG STRUCTURE; PRIORITY JOURNAL;

ANTIBIOTICS, ANTINEOPLASTIC; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOXORUBICIN; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HYDROLYSIS; PRODRUGS; TUMOR CELLS, CULTURED;

EID: 0032440521     PISSN: 02669536     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. BAGSHAWE, K.D. (1987). Antibody directed enzymes revive anti-cancer prodrugs concept. British Journal of Cancer, 56, 531.
2. BOSSLET, K., CZECH, J., LORENZ, P., SEDLACEK, H.H., SCHUERMANN, M. & SEEMANN, G. (1992). Molecular and functional characterisation of a fusion protein suited for tumour specific prodrug activation. British Journal of Cancer, 65, 234.
3. BOSSLET, K., CZECH, J. & HOFFMANN, D. (1994). Tumor-selective prodrug activation by fusion protein-mediated catalysis. Cancer Research, 54, 215.
4. BOSSLET, K., CZECH, J. & HOFFMANN, D. (1995). A novel one-step tumor-selective prodrug activation system. Tumor Targeting, 1, 45.
5. BOSSLET, K., STRAUB, R., BLUMRICH, M., CZECH, J., GERKEN, M., SPERKER, B., KROEMER, U.K., GESSON, J.-P., KOCH, M. & MONNERET, C. (1998). Elucidation of the mechanism enabling tumor selective prodrug monotherapy. Cancer Research, 58, 1195.
6. CRAMER, F., BARH, P., RHAESE, H.J., SANGER, W., SCHEIT, K.H., SCHNEIDER, G. & TENNIGKEIT, J. (1963). Stabilität von Schutzgruppen für Nucleoside und Nucleotide, Tetrahedron Letters, 16, 1039.
7. DEONARAIN, M.P. & EPENETOS, A.A. (1994). Targeting enzymes for cancer therapy: old enzymes in new roles. British Journal of Cancer, 70, 786.
8. FLORENT, J.-C., DONG, X., GAUDEL, G., MITAKU, S., MONNERET, C., GESSON, J.-P., JACQUESY, J.-C., MONDON, M., RENOUX, B., ANDRIANOMENJANAHARY, S., MICHEL, S., KOCH, M., TILLEQUIN, F., GERKEN, M., CZECH, J., STRAUB, R. & BOSSLET, K. J. (1998). Prodrugs of anthracyclines for use in Antibody-Directed Enzyme Prodrug Therapy. Journal of Medicinal Chemistry, 41, 3572.
9. GESSON, J.-P., JACQUESY, J.-C., MONDON, M., PETIT, P., RENOUX, B., ANDRIANOMENJANAHARY, S., DUFAT-TRINH VAN, H., KOCH, M., MICHEL, S., TILLEQUIN, F., FLORENT, J.-C., MONNERET, C., BOSSLET, K., CZECH, J. & HOFFMANN, D. (1994). Prodrugs of anthracyclines for chemotherapy via enzyme-monoclonal antibody conjugates. Anti-Cancer Drug Design, 9, 409.
10. HAISMA, H.J., VAN MUIJEN, M., PINEDO, H.M. & BOVEN, E. (1994). Comparison of two anthracycline-based prodrugs for activation by a monoclonal antibody-β-glucuronidase conjugate in the specific treatment of cancer. Cell Biophysics, 24-25, 185.
11. HAISMA, H.J., BRAKENHOFF, R.H., MEULEN-MUILEMAN, I.V.D. PINEDO, H.M. & BOVEN, E. (1998). Construction and charaterization of a fusion protein of single-chain anti-carcinoma antibody 323/A3 and human β-glucuronidase. Cancer Immunology & Immunotherapy, 45, 266.